Trial Profile
A PhaseⅠStudy of Apatinib Mesylate (YN968D1) 1,000mg in Patients With Unresectable Locally Advanced or Metastatic Gastric Cancer Failed to Standard Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Jul 2022
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions
- Sponsors Bukwang Pharmaceutical
- 20 Jul 2022 Status changed from active, no longer recruiting to completed.
- 09 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Jan 2017 Status changed from not yet recruiting to recruiting.